Stoke Therapeutics, Inc. - Common Stock (STOK)

STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's strategy.

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.